(Incorporated in Delaware)

We are a clinical-stage biopharmaceutical company whose leading drug candidate, BHB-1893, is being evaluated to treat patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.

HCM is a chronic, progressive disease characterized by abnormal thickening and impaired relaxation of the heart. HCM is associated with significant morbidity, reduced quality of life, and an increased risk of heart failure and sudden cardiac death. HCM affects more than 700,000 individuals in the United States and remains an area of significant unmet medical need.

Our goal is to improve the treatment options for these patients.

BHB-1893 was initially discovered and developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui”) in China. We in-licensed BHB-1893 pursuant to an exclusive license agreement with Hengrui (the “Exclusive License Agreement”), and as such, all clinical trials of BHB-1893 completed to date were designed, sponsored, and conducted by Hengrui, primarily in China, with one Phase 1 trial conducted in Australia. We were not involved in the design, conduct, or oversight of these trials.

We plan to advance BHB‑1893 through global Phase 3 development in both obstructive HCM (oHCM) and non-obstructive HCM (nHCM). We expect to initiate LIONHEART-HCM, our global Phase 3 trial in oHCM, in the second half of 2026 and NOBLEHEART-HCM, our global Phase 3 trial in nHCM in the first half of 2027. In addition to our planned global Phase 3 trials in oHCM and nHCM, Hengrui is conducting a Phase 2 trial of HRS-1893 in heart failure with preserved ejection fraction (“HFpEF”), in Greater China, with expected data readouts in the second half of 2027.

Note: Net loss is for the 12 months that ended on March 31, 2026. The company has not generated any product revenue, according to the prospectus.

(Note: Braveheart Bio disclosed the terms for its IPO on July 30, 2026, in an S-1/A filing: 18.8 million shares at a price range of $15.00 to $17.00 to raise $300 million, if priced at the $16.00 mid-point of its range. Background: Braveheart Bio filed its S-1 for its IPO on July 15, 2026, without disclosing the terms. Estimated proceeds were $100 million, a placeholder figure.)